Calgary, January 27, 2026 – Northern RNA Inc. has once again been recognized by BioTalent Canada as an I.D.E.A.L. Bioscience Employer™ for 2025-2026, marking the third consecutive year the organization has received this distinction.
This continued recognition reflects Northern RNA’s ongoing commitment to embedding IDEA best practices, Inclusivity, Diversity, Equity, and Accessibility, into its culture and operations while contributing to a strong and resilient Canadian bio‑economy.
“We are incredibly proud to be recognized as a 2026 I.D.E.A.L. Bioscience Employer for the third year in a row,” says Dr. Jared Davis, President & Chief Technology Officer “Achieving this distinction multiple times is a testament to the culture we are building, one that champions innovation, collaboration, and excellence across Canada’s life sciences and biomanufacturing sectors. This recognition reinforces that our efforts are making an impact, and we remain committed to continuous improvement as we help shape the future of biomanufacturing in Canada.”
Each year, BioTalent Canada, a national workforce development council, recognizes organizations in the bio-economy, both large and small, that demonstrate leadership in IDEA. Applicants undergo a rigorous evaluation based on seven key criteria that measure how IDEA is integrated into organizational strategy, leadership and organizational outcomes.
Employers are evaluated on their ability to:
- Align IDEA with organizational vision, values and strategies
- Demonstrate leadership accountability for IDEA outcomes
- Measure and assess IDEA efforts
- Prioritize IDEA learning and awareness
- Implement inclusive talent management practices
- Foster a culture of belonging
- Engage with external collaborators such as communities, clients, and suppliers
Following this year’s comprehensive evaluation, Northern RNA Inc. was named one of 23 recipients recognized as 2026 I.D.E.A.L. Bioscience Employers.
“Recognition as an I.D.E.A.L. Bioscience Employer is a differentiator in today’s market,” says Rob Henderson, President and CEO of BioTalent Canada. “It tells job seekers, partners, and investors that your organization is committed to excellence, not just in science, but in the way you support and develop your people. Diversity and inclusion are not a charitable endeavor – every study out there indicates it’s a smart way of building your company.”
For more information about the I.D.E.A.L. Bioscience Employer™ program and the 2025–2026 recipients, visit biotalent.ca/IDEALEmployer.
About BioTalent Canada:
BioTalent Canada supports the people behind life-changing science. Trusted as the go-to source for labour market intelligence, BioTalent Canada guides bio-economy contributors with evidence-based data and industry-driven standards. BioTalent Canada, as a workforce development council, is focused on igniting the industry’s brainpower, bridging the gap between job-ready talent and employers, and ensuring the long-term agility, resiliency, and sustainability of one of Canada’s most vital sectors.
BioTalent Canada has received varied distinctions following a thorough and independent analysis of the organization. By practicing the same industry standards it recommends to partners, the organization has been honored with the following titles:
- Great Place to Work® Employer from 2019-2025 and one of the Best Workplaces in Healthcare for 2023 by Great Place to Work Canada®
- The Best Leader in Diversity, Equity, and Inclusion at the 2024 Best Ottawa Business Awards
- 2024 Collaboration Catalyst by Magnet Network
- One of Canada’s Best Places to Work by HRD Canada for 2024
- 5-Star Diversity, Equity and Inclusion Employer by Canadian HR Reporter since 2023
- Employer of Choice by Canadian HR Reporter for 2025
For more information, please visit biotalent.ca.
About Northern RNA
Founded in 2020 to address unmet global demand for the manufacturing of vaccines and vaccine components, Northern RNA is a leading Contract Development and Manufacturing Organization (CDMO) specializing in the manufacturing and production of Nucleic Acid products used in applications including mRNA vaccines, DNA vaccines, mRNA therapies, Gene Editing and Gene therapies. Our goal is to provide secure, clinical to commercial scale, GMP-grade manufacturing for our customers across the globe.
For more information, please visit northernrna.com
Media Inquiries
Thomas Hansen
Vice President Corporate Affairs
Northern RNA.
Email: thansen@northernrna.com phone : 430-200-2568